SFEBES2021 Poster Presentations Metabolism, Obesity and Diabetes (78 abstracts)
1Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria; 2Obafemi Awolowo University, Ile-Ife, Nigeria; 3Afe Babalola University, Ado-Ekiti, Nigeria; 4Evercare Hospital, Lekki, Nigeria
Background: T2DM has been described as a complex mix bag of insulin resistance and β-cell defects in varying proportions. Several works have described in quantitative terms insulin resistance among diabetics and its relationship with proteinuria, the relative contribution of β- cell dysfunction have largely been extrapolated. This work is an attempt to provide the missing link in our clime.
Objectives: The study aims to describe, in quantitative terms, β-cell (dys)function and explore its relationship with proteinuria in diabetics.
Methodology: A cross-sectional study of selected T2DM patients. Relevant data were obtained on demographics and anthropometry. Samples were drawn for FPG, Insulin, Creatinine and Albumin. eGFR was calculated with CKD-EPI. β-cell function was derived from computation of insulin and FPG from a calculator HOMA2 v2.2.3. Data was analysed with SPSS V22
Results: There were 83 subjects made up of 30 (36.1%) male and 53(63.9%) female. The mean age was 56.1yrs, while the average duration of DM was 1.4yr. About 2/3rd reported had hypertension but mean SBP/DBP was 131.4/77.3mmHg. Nearly half complained of frothy urine, but none reported oedema. The mean values of FPG, HBA1C, HOMA%β, and eGFR were 6.5mmol/l; 7%, 58.9%, and 78 ml/min/1.73m2. About 50% had proteinuria of which > 75% was microalbuminuria. Subjects with poor control had significantly lower mean values of β-cell function (HOMA%β: 29.5% Vs 78.8%). There was no correlation between β-cell function and ACR. There was a significant positive correlation between β-cell function and measures of glycaemic control.
Conclusions: β-cell dysfunction remains a major feature in of our diabetics and even when not related to proteinuria may indeed connote poor metabolic control and adverse CVS outcome. Routine assessment of β-cell function in the management of T2DM may not be substantiated, nonetheless, physicians should be aware of the significant burden of β-cell dysfunction as this may influence the choice of therapy.